Indeed, TAAR1/DA D2 receptor interactions, and their downstream signalling pathways converging on GSK-3, may provide alternative targets for the development of new treatments not only for stimulant addiction but also for other disorders involving DA dysfunction, including schizophrenia and bipolar disorder. This evidence concerns the gene TAAR1 and bipolar disorder.